AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9624308 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sublingual melatonin
Number of subjects: 18
Study 9624308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8895290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV (Group O)
Number of subjects: 200
Study 8895290 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 0.625 mg IV plus Metoclopramide 10 mg IV (Group DM)
Number of subjects: 200
Study 2270942 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard metre rod for accuracy check
Number of subjects: 240
Study 2270942 — intervention group
Group type: EXPERIMENTAL
Intervention: Two experienced observers measuring height
Number of subjects: 240
Study 2270942 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-blind and non-randomised measurements
Number of subjects: 240
Study 7373324 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiperomide
Number of subjects: 10
Study 7373324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31685256 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheimpflug tomography pachymetry map and posterior elevation map patterns
Number of subjects: 96
Study 31685256 — intervention group
Group type: COMPARATOR
Intervention: None, 1 or 2, and all 3 pachymetry map and posterior elevation map parameters
Number of subjects: 96
Study 31685256 — intervention group
Group type: COMPARATOR
Intervention: None, 1 or 2, and all 3 pachymetry map and posterior elevation map parameters after uncomplicated cataract surgery
Number of subjects: 96
Study 30260474 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, nab-paclitaxel, and ixabepilone
Number of subjects: 468
Study 30260474 — intervention group
Group type: COMPARATOR
Intervention: Clinical covariates alone
Number of subjects: 468
Study 26292026 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe boat technique
Number of subjects: 90
Study 26292026 — intervention group
Group type: COMPARATOR
Intervention: I/A tip
Number of subjects: 90
Study 26292026 — intervention group
Group type: COMPARATOR
Intervention: Phaco tip
Number of subjects: 90
Study 26945692 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block
Number of subjects: 50
Study 26945692 — intervention group
Group type: COMPARATOR
Intervention: Rectus sheath block
Number of subjects: 50
Study 25256137 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-20 for 1 week followed by 3 weeks of concomitant MS-20 plus chemotherapy
Number of subjects: 143
Study 25256137 — intervention group
Group type: EXPERIMENTAL
Intervention: MS-20 treatment
Number of subjects: 143
Study 25256137 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy for 3 weeks
Number of subjects: 143
Study 21095627 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivabradine for 5 days prior to CTCA
Number of subjects: 123
Study 21095627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic beta-blockade (atenolol 50mg twice a day for 5 days prior to CTCA)
Number of subjects: 123
Study 21095627 — intervention group
Group type: COMPARATOR
Intervention: No additional premedication (Control group)
Number of subjects: 123
Study 21095627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic beta-blockade and ivabradine
Number of subjects: 123
Study 20081712 — intervention group
Group type: EXPERIMENTAL
Intervention: EROMIA software for electronic recording of patient data
Number of subjects: 0
Study 18053198 — intervention group
Group type: EXPERIMENTAL
Intervention: Merional administered subcutaneously (s.c.)
Number of subjects: 160
Study 18053198 — intervention group
Group type: COMPARATOR
Intervention: Merional administered intramuscularly (i.m.)
Number of subjects: 160
Study 16252535 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect resin composite onlays
Number of subjects: 47
Study 16252535 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic onlays
Number of subjects: 47
Study 16252535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both indirect resin composite and ceramic onlays
Number of subjects: 47
Study 16252535 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study 11889294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume, pressure-limited ventilation (LVPLV) in group 1 (septic patients)
Number of subjects: 22
Study 11889294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume, pressure-limited ventilation (LVPLV) in group 2 (nonseptic patients)
Number of subjects: 22
Study 8996744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 450 mg clindamycin (CLDM) three times daily for 7 days
Number of subjects: 100
Study 8996744 — intervention group
Group type: COMPARATOR
Intervention: Vaginal administration of 2% CLDM phosphate in cream (self-made) 5 g once a day for 7 days
Number of subjects: 100
Study 8996744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 450 mg CLDM
Number of subjects: 100
Study 8996744 — intervention group
Group type: COMPARATOR
Intervention: Vaginal administration of 2% CLDM phosphate in cream
Number of subjects: 100
Study 8217999 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 50 mg/day (n = 103)
Number of subjects: 208
Study 8217999 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 50 mg/day (n = 10)
Number of subjects: 208
Study 8217999 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 105)
Number of subjects: 208
Study 3618879 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking
Number of subjects: 0
Study 3618879 — intervention group
Group type: EXPERIMENTAL
Intervention: Riding a stationary cycle
Number of subjects: 0
Study 3618879 — intervention group
Group type: COMPARATOR
Intervention: Swimming laps in a pool
Number of subjects: 0
Study 29659405 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% hydroquinone (HQ) cream
Number of subjects: 40
Study 29659405 — intervention group
Group type: COMPARATOR
Intervention: Moisturizer
Number of subjects: 40
Study 26579704 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 69
Study 26579704 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 69
Study 25057035 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH+ (100 μg GnRH)
Number of subjects: 823
Study 25057035 — intervention group
Group type: COMPARATOR
Intervention: GnRH- (no GnRH)
Number of subjects: 823
Study 22972218 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating on the non-affected hand
Number of subjects: 39
Study 20395554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (n = 60)
Number of subjects: 239
Study 20395554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 239
Study 20395554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 239
Study 20395554 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 179)
Number of subjects: 239
Study 18373877 — intervention group
Group type: EXPERIMENTAL
Intervention: Early childhood obesity prevention intervention delivered to first-time parents over the infant's first 18 months of life.
Number of subjects: 600
Study 18373877 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 600
Study 16001645 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 25
Study 11802250 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway inflation pressure set to 2.7 kPa
Number of subjects: 32
Study 11802250 — intervention group
Group type: COMPARATOR
Intervention: Airway inflation pressure set to 3.0 kPa
Number of subjects: 32
Study 10887873 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol for screening delirium
Number of subjects: 0
Study 10887873 — intervention group
Group type: COMPARATOR
Intervention: Standard assessment practices
Number of subjects: 0
Study 7782725 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabica oil (2 g per day)
Number of subjects: 11
Study 7782725 — intervention group
Group type: EXPERIMENTAL
Intervention: Robusta oil (2 g per day)
Number of subjects: 11
Study 7782725 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 11
Study 1649269 — intervention group
Group type: EXPERIMENTAL
Intervention: Acivicin (AT‐125)
Number of subjects: 32
Study 6414821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg b.d. (oral)
Number of subjects: 43
Study 6414821 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate 20 mg q.i.d. (inhalation)
Number of subjects: 43
Study 6414821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 43
Study 6414821 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate
Number of subjects: 43
Study 6414821 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician preferences
Number of subjects: 43
Study 31718678 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target (T2T) therapy aimed at DAS28-ESR remission
Number of subjects: 229
Study 31718678 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) assessments
Number of subjects: 229
Study 29268805 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding for infants aged <6 months
Number of subjects: 477
Study 29268805 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding continuation at 1 year
Number of subjects: 477
Study 29268805 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding continuation at 2 years
Number of subjects: 477
Study 29268805 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle-feeding prevalence for children aged <2 years
Number of subjects: 477
Study 29268805 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid food introduction for infants aged 6-8 months
Number of subjects: 477
Study 29268805 — intervention group
Group type: EXPERIMENTAL
Intervention: Reason for discontinuation of breast-feeding due to conflict stress
Number of subjects: 477
Study 27652977 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE-MRI parameters (ΔAreamax and ΔSlopemax)
Number of subjects: 170
Study 27652977 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model using DCE-MRI parameters
Number of subjects: 170
Study 27652977 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-predicted pCR
Number of subjects: 170
Study 24476987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge (4 mg) with expectancy
Number of subjects: 70
Study 24476987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine expectancy (without actual nicotine administration)
Number of subjects: 70
Study 24476987 — intervention group
Group type: COMPARATOR
Intervention: Exposure to smoking-related stimuli
Number of subjects: 70
Study 24476987 — intervention group
Group type: COMPARATOR
Intervention: Women following smoking cue
Number of subjects: 70
Study 23109475 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh broccoli soup
Number of subjects: 18
Study 23109475 — intervention group
Group type: COMPARATOR
Intervention: Frozen broccoli soup
Number of subjects: 18
Study 20889139 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal intervention
Number of subjects: 156
Study 20889139 — intervention group
Group type: COMPARATOR
Intervention: No periodontal intervention
Number of subjects: 156
Study 18198648 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI), antibiotics, and short-term pulse therapy with high efficient hormone
Number of subjects: 80
Study 18198648 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics and hormone pulse therapy
Number of subjects: 80
Study 16402538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pioglitazone (15 mg to 45 mg)
Number of subjects: 5238
Study 16402538 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5238
Study 12402725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 20 micrograms
Number of subjects: 75
Study 12402725 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 300 micrograms
Number of subjects: 75
Study 12402725 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 75
Study 9502570 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-charged dialysate (9.17 mmol/l or 165 mg/dl)
Number of subjects: 5
Study 9502570 — intervention group
Group type: COMPARATOR
Intervention: Glucose-free dialysate
Number of subjects: 5
Study 9502570 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-charged dialysate
Number of subjects: 5
Study 8569931 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment
Number of subjects: 24
Study 2757899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg cilazaprilat
Number of subjects: 8
Study 2757899 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg cilazaprilat
Number of subjects: 8
Study 2757899 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg cilazaprilat
Number of subjects: 8
Study 2757899 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of cilazaprilat
Number of subjects: 8
Study 30765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 264
Study 30765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 31772346 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior to injury
Number of subjects: 410
Study 31772346 — intervention group
Group type: EXPERIMENTAL
Intervention: After injury
Number of subjects: 410
Study 31096576 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifier for identifying DAT candidates
Number of subjects: 112
Study 28806303 — intervention group
Group type: EXPERIMENTAL
Intervention: FFT (Full Fast Track) management
Number of subjects: 263
Study 28806303 — intervention group
Group type: COMPARATOR
Intervention: LFT (Limited Fast Track) management
Number of subjects: 263
Study 25800548 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐I/ARB treatment
Number of subjects: 0
Study 25800548 — intervention group
Group type: COMPARATOR
Intervention: Diuretic treatment
Number of subjects: 0
Study 22864470 — intervention group
Group type: EXPERIMENTAL
Intervention: Land exercise
Number of subjects: 98
Study 22864470 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise
Number of subjects: 98
Study 22864470 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study 21248589 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar fusion plus anterior support (PLF + ALIF)
Number of subjects: 92
Study 21248589 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral lumbar fusion alone
Number of subjects: 92
Study 21248589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PLF + ALIF and posterolateral fusion)
Number of subjects: 92
Study 18070786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric articaine 80 mg
Number of subjects: 80
Study 18070786 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine 15 mg
Number of subjects: 80
Study 16960699 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily
Number of subjects: 0
Study 16960699 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg daily
Number of subjects: 0
Study 16960699 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg daily
Number of subjects: 0
Study 16960699 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg daily
Number of subjects: 0
Study 16960699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12635350 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 21
Study 11460275 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/pyrophosphate dentifrice slurry
Number of subjects: 34
Study 11460275 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice slurry
Number of subjects: 34
Study 11460275 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/pyrophosphate dentifrice
Number of subjects: 34
Study 9090340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy
Number of subjects: 120
Study 9090340 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (fluoxetine) plus psychological treatment
Number of subjects: 120
Study 9090340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy plus medication
Number of subjects: 120
Study 9090340 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy plus medication
Number of subjects: 120
Study 9090340 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus psychological treatment
Number of subjects: 120
Study 8224258 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian cautery with application of Interceed Adhesion Barrier
Number of subjects: 8
Study 8224258 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Interceed application)
Number of subjects: 8
Study 3708122 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-unit pellets (intervention)
Number of subjects: 12
Study 3708122 — intervention group
Group type: COMPARATOR
Intervention: Single-unit tablets (control)
Number of subjects: 12
Study 31574303 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr) plus maximally tolerated guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 31574303 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 614
Study 31574303 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr)
Number of subjects: 614
Study 30354935 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 112
Study 30354935 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy (ART) plus chemotherapy
Number of subjects: 112
Study 30354935 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients showing a response to the tumor (complete or partial)
Number of subjects: 112
Study 27406975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for 1 year
Number of subjects: 14918
Study 25022111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupoint catgut embedding therapy + acupuncture-moxibustion)
Number of subjects: 69
Study 25022111 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture-moxibustion group
Number of subjects: 69
Study 25022111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy group
Number of subjects: 69
Study 22533679 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin theta (s.c.)
Number of subjects: 288
Study 22533679 — intervention group
Group type: COMPARATOR
Intervention: Epoetin beta (s.c.)
Number of subjects: 288
Study 20547421 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs‐led package of care (therapy based on cognitive behaviour therapy, ethnically matched therapists, advocacy and mentoring; 'rapid access')
Number of subjects: 40
Study 20547421 — intervention group
Group type: COMPARATOR
Intervention: 3‐month waiting list control with information on local mental health services ('standard access')
Number of subjects: 40
Study 18176646 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin Composite (RCO) - Clearfil DC Core Automix
Number of subjects: 40
Study 18176646 — intervention group
Group type: EXPERIMENTAL
Intervention: Reforpins (REF) - Two Reforpins
Number of subjects: 40
Study 18176646 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin Cement (RCE) - Panavia F 2.0
Number of subjects: 40
Study 18176646 — intervention group
Group type: COMPARATOR
Intervention: Control Group (DEN) - Non-flared canals
Number of subjects: 40
Study 15959635 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisalign system
Number of subjects: 30
Study 15959635 — intervention group
Group type: COMPARATOR
Intervention: Fixed orthodontic appliances
Number of subjects: 30
Study 12883205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus, prednisone, and tacrolimus or cyclosporine
Number of subjects: 15
Study 12883205 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus, prednisone, and mycophenolate mofetil (Control)
Number of subjects: 15
Study 10559567 — intervention group
Group type: EXPERIMENTAL
Intervention: Denbufylline 25, 50 or 100 mg
Number of subjects: 336
Study 10559567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 8903288 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine NGD
Number of subjects: 76
Study 8903288 — intervention group
Group type: COMPARATOR
Intervention: Selective NGD
Number of subjects: 76
Study 8903288 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective NGD (no intubation)
Number of subjects: 76
Study 8903288 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective NGD (requiring intubation)
Number of subjects: 76
Study 8903288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 1992187 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide, 300 micrograms/24 h for 12 weeks
Number of subjects: 11
Study 1992187 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 11
Study 6345257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine for 2 weeks
Number of subjects: 120
Study 6345257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine for 4 weeks
Number of subjects: 120
Study 6345257 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 120
Study 31532795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 fatty acids (O-3FA) for 6 months
Number of subjects: 312
Study 31532795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 27465634 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NORM: FiO2 = 0.21)
Number of subjects: 12
Study 27465634 — intervention group
Group type: EXPERIMENTAL
Intervention: High hypoxia (HH: FiO2 = 0.13)
Number of subjects: 12
Study 27465634 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (MH: FiO2 = 0.16)
Number of subjects: 12
Study 25300348 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose rinse
Number of subjects: 20
Study 25300348 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% urea rinse
Number of subjects: 20
Study 25300348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rinse)
Number of subjects: 20
Study 23825432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslexic children
Number of subjects: 76